Alzheimer disease (AD), also known as senile dementia, is a primary degenerative brain disease that occurs in old age and early senility. It refers to a persistent high-grade neurological activity disorder. The disease started insidiously and the course of the disease was chronic progressive. It is mainly manifested as neurocognitive symptoms such as progressive memory impairment, cognitive dysfunction, personality change and language disorder, which seriously affect social, occupational and life functions.
 Gatz M, Reynolds C A, Fratiglioni L, et al. Role of Genes and Environments for Explaining Alzheimer Disease [J]. Arch Gen Psychiatry, 2006, 63(2):168-174.
 Bertram L, Lill C M, Tanzi R E. The genetics of Alzheimer disease: back to the future [J]. Neuron, 2010, 68(2):270-281.
 Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care [J]. Lancet, 2017, 390(10113).
 Harvey R, Skelton-Robinson M, Rossor M. The prevalence and causes of dementia in people under the age of 65 years [J]. Journal of Neurology Neurosurgery & Psychiatry, 2003, 74(9):1206.
 Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease [J]. Nature Reviews Neurology, 2011, 7(3):137-152.
 Chan K Y, Wang W, Wu J J, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis [J]. The Lancet,2013, 381(9882): 2016-2023.
 Querfurth H W, Laferla F M. Alzheimer's disease [J]. N Engl J Med, 2010, 362(4):329-344.
 Savage M J, Lin Y G, Ciallella J R, et al. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition [J]. Journal of Neuroscience the Official Journal of the Society for Neuroscience, 2002, 22(9):3376.
 Shoji M, Iwakami N, Takeuchi S, et al. JNK activation is associated with intracellular beta-amyloid accumulation [J]. Molecular Brain Research, 2000, 85(1-2):221-233.
 CristianaAtzori, BernardinoGhetti, RobertoPiva, et al. Activation of the JNK/p38 Pathway Occurs in Diseases Characterized by Tau Protein Pathology and Is Related to Tau Phosphorylation But Not to Apoptosis [J]. J Neuropathol Exp Neurol, 2001, 60(12):1190-1197.
 Lafay-Chebassier C, Paccalin M, Page G, et al. mTOR/p70S6k signalling alteration by A-beta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease [J]. Journal of Neurochemistry, 2005, 94(1):215-225.
 Grimm MO1, Hundsdörfer B, Grösgen S, et al. PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer's disease [J] . Cell Physiol Biochem, 2014, 34: 92-110.
 Boonen R A, Van T P, Zivkovic D. Wnt signaling in Alzheimer's disease: up or down, that is the question [J]. Ageing Research Reviews, 2009, 8(2):71-82.
 Dubois B, Feldman H H, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria [J]. Lancet Neurology, 2007, 6(8):734-746.
 Dubois B, Feldman H H, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria [J]. Lancet Neurology, 2014, 13(6):614-629.
 Maccioni RB, Lavados M, Guillón M, et al. Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects [J].Neurobiology of Aging, 2006, 27(2):237-244.
 Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.[J]. Lancet Neurology, 2006, 5(3):228.
 Shal B, Ding W, Ali H, et al. Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease [J]. Frontiers in Pharmacology, 2018, 9:548.
 Tan M S, Yu J T, Tan C C, et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis [J]. Journal of Alzheimers Disease Jad, 2015, 43(2):589-603.
 Henderson V W. Three Midlife Strategies to Prevent Cognitive Impairment Due to Alzheimer's Disease [J]. Climacteric, 2014, 17(2):38.
 Larsson S C, Markus H S. Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer's Disease? A Systematic Review and Meta-Analysis [J]. Journal of Alzheimers Disease, 2018, 64(2):1-12.
 Katsouri L, Parr C, Bogdanovic N, et al. PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism.[J]. Journal of Alzheimers Disease Jad, 2011, 25(1):151-62.
 Katsouri L, Lim Y M, Blondrath K, et al. PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model [J]. Proc Natl Acad Sci USA, 2016, 113(43):12292-12297.